Home
Resource
Multicomponent targeted proapoptotic anticancer drug delivery system
PDF
PDF format is widely accepted and good for printing.
Plug-in required
PDF-1(1.65 MB)
Citation & Export
View Usage Statistics
Staff View

Citation & Export
Hide

Simple citation

Chandna, Pooja. Multicomponent targeted proapoptotic anticancer drug delivery system. Retrieved from https://doi.org/doi:10.7282/T3GX49X3

Export

Click here for information about Citation Management Tools at Rutgers.

Statistics
Hide

Description

TitleMulticomponent targeted proapoptotic anticancer drug delivery system
NameChandna, Pooja (author); Minko, Tamara (internal member); Michniak, Bozena (internal member); You, Goufeng (internal member); Paranjpe, Pankaj (outside member); Rutgers University; Graduate School - New Brunswick
Date Created2011
Other Date2011-05 (degree)
SubjectPharmaceutical Science, Drug delivery systems, Cancer--Treatment
Extentxix, 154 p. : ill.
DescriptionCancer is one of the leading causes of death in United States. The current approaches for the treatment of solid tumor available are the surgery for the removal of primary tumor followed by chemotherapy and /or radiation. The efficacy of chemotherapy is limited by the following factors; (1) adverse side-effects on healthy organs, (2) development of cellular resistance and (3) low solubility of many anticancer drugs. The primary objective of this dissertation is to overcome all the above stated limitations. The methods employed in this dissertation includes designing, synthesizing and evaluating a novel drug delivery system comprising of 1) multiple copies of an anticancer drug, Camptothecin (CPT) ; 2) a polymeric carrier, Polyethylene glycol (PEG); 3) multiple copies of a targeting moiety to cancer cells, Luteinizing hormone releasing hormone (LHRH) peptide; 4) multiple copies of a suppressor of antiapoptotic cellular defense, BH3 peptide both in vitro and in vivo on A2780 human ovarian carcinoma cells and malignant ascites and animal models respectively. Conjugates of CPT, LHRH and CPT, LHRH, BH3 were evaluated for cytotoxicity, cancer specificity and antitumor activity. The multicomponent anticancer delivery system will significantly enhance the efficacy of an anticancer drug in the treatment of all the stages of cancer when compared with free drug, non-targeted delivery systems or the system consisting of one copy of each active component.
NotePh.D.
NoteIncludes bibliographical references
NoteIncludes vita
Noteby Pooja Chandna
Genretheses, ETD doctoral
Persistent URLhttps://doi.org/doi:10.7282/T3GX49X3
Languageeng
CollectionGraduate School - New Brunswick Electronic Theses and Dissertations
Organization NameRutgers, The State University of New Jersey
RightsThe author owns the copyright to this work.
Version 8.5.5
Rutgers University Libraries - Copyright ©2024